source
- Helus Pharma reports Phase 3 depression trial shows symptom improvement but safety concerns lingerHelus Pharma, a psychedelics-focused company, announced results of its Phase 3 trial for its lead depression drug. The trial showed the drug produced greater improvement in depression symptoms com…
- Novo’s CagriSema shows over 20% weight loss at low doses in Phase 3 trialNovo Nordisk presented new Phase 3 data on its experimental obesity combo CagriSema at ObesityWeek 2026. The low‑dose arm (1 mg and 1.7 mg weekly) achieved average weight reductions of about 21% a…